Thumbnail Image
Publication

Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.

Wang-Gillam, A
; 
Li, C
; 
Bodoky, G
; 
Dean, A
; 
Shan, Y
; 
Jameson, G
; 
Macarulla, T
; 
Lee, K
; 
Cunningham, D
; 
Blanc, J
... show 10 more
Citations
Altmetric:
Abstract
Nanoliposomal irinotecan showed activity in a phase 2 study in patients with metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based therapies. We assessed the effect of nanoliposomal irinotecan alone or combined with fluorouracil and folinic acid in a phase 3 trial in this population.
Authors
Wang-Gillam, A
Li, C
Bodoky, G
Dean, A
Shan, Y
Jameson, G
Macarulla, T
Lee, K
Cunningham, D
Blanc, J
Hubner, Richard A
Chiu, C
Schwartsmann, G
Siveke, J
Braiteh, F
Moyo, V
Belanger, B
Dhindsa, N
Bayever, E
Von Hoff, D
Chen, L
Affiliation
Washington University School of Medicine, St Louis, MO, USA
Description
Date
2015-11-29
Publisher
Collections
All Christie Publications
Show all metadata
Keywords
Type
Article
Citation
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. 2015: Lancet
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/593002
Embedded videos